Candriam Luxembourg S.C.A. increased its stake in shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) by 14.5% during the second quarter, Holdings Channel reports. The institutional investor owned 709,900 shares of the biopharmaceutical company’s stock after buying an additional 90,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Amicus Therapeutics were worth $3,876,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of FOLD. Pacad Investment Ltd. boosted its stake in Amicus Therapeutics by 42.9% in the first quarter. Pacad Investment Ltd. now owns 83,990 shares of the biopharmaceutical company’s stock valued at $710,000 after buying an additional 25,231 shares in the last quarter. Teachers Advisors Inc. raised its stake in shares of Amicus Therapeutics by 1.0% in the first quarter. Teachers Advisors Inc. now owns 173,294 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 1,750 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Amicus Therapeutics by 1.6% in the first quarter. BlackRock Fund Advisors now owns 5,444,399 shares of the biopharmaceutical company’s stock valued at $46,005,000 after buying an additional 83,654 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Amicus Therapeutics during the first quarter valued at about $157,000. Finally, Wexford Capital LP acquired a new stake in shares of Amicus Therapeutics during the first quarter valued at about $1,095,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.
Amicus Therapeutics Inc. (NASDAQ:FOLD) traded up 4.67% on Friday, hitting $7.40. 1,839,436 shares of the stock traded hands. Amicus Therapeutics Inc. has a 52 week low of $4.98 and a 52 week high of $11.78. The firm’s market capitalization is $1.05 billion. The stock has a 50 day moving average of $7.16 and a 200 day moving average of $6.95.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. Equities research analysts anticipate that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.
Several brokerages have issued reports on FOLD. Zacks Investment Research lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Chardan Capital set a $15.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $19.00 price target (up from $17.00) on shares of Amicus Therapeutics in a research note on Tuesday, June 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. Amicus Therapeutics currently has an average rating of “Buy” and a consensus price target of $12.19.
In other news, insider Jay Barth sold 20,916 shares of the business’s stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $7.00, for a total transaction of $146,412.00. Following the completion of the sale, the insider now owns 25,458 shares in the company, valued at $178,206. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Perceptive Advisors Llc sold 1,100,000 shares of the business’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $6.81, for a total value of $7,491,000.00. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.